Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talimogene Laherparepvec in pediatric advanced non-CNS tumors
NCT02756845Phase 1Completed
- Sponsor
- Amgen
- Start
- Aug 2017
- Primary completion
- Jan 2022
- Modality
- Oncolytic Viruses
- Countries
- 7
01
Overview
Phase 1, open-label, single-arm trial of talimogene laherparepvec in solid tumor, sponsored by Amgen. Primary endpoint: Dose-limiting Toxicity at Day 35. Started Aug 2017; status: completed.
02
Drugs
talimogene laherparepvec
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02756845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02756845.